Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111292 | 0.86 | ESR2 (0.35) | CYP3A4CYP2C9APPFFAR4ESR2 | |
| SCHEMBL20102612 | 0.82 | SPHK1 (0.36) | CYP2C9 | |
| SCHEMBL20102577 | 0.79 | MEN1 (0.34) | CYP3A4CYP2C9FFAR4ESR2 | |
| SCHEMBL20111489 | 0.77 | — | — | |
| SCHEMBL20102579 | 0.77 | MEN1 (0.33) | CYP2C9ESR2 | |
| SCHEMBL20111497 | 0.76 | ESR2 (0.45) | CYP3A4CYP2C9APPFFAR4ESR2 | |
| SCHEMBL20117586 | 0.74 | ALDH1A1 (0.32) | FFAR4 | |
| SCHEMBL20111248 | 0.73 | QRFPR (0.36) | — | |
| SCHEMBL20111309 | 0.73 | CYP3A4 (0.40) | CYP3A4CYP2C9APPFFAR4 | |
| SCHEMBL20111534 | 0.71 | SPHK1 (0.37) | FFAR4FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | CYP3A4 576/4885CYP2C9 927/4885APP 1118/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | CYP3A4 576/4885CYP2C9 927/4885APP 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.